Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
Sandeep Vasant More, Dong‐Kug Choi
Molecular Neurodegeneration (2015) Vol. 10, Iss. 1
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
Qiuyang Zheng, Timothy Y. Huang, Lishan Zhang, et al.
Frontiers in Aging Neuroscience (2016) Vol. 8
Open Access | Times Cited: 273
Microglia activation states and cannabinoid system: Therapeutic implications
Míriam Mecha, Francisco Carrillo‐Salinas, Ana Feliú, et al.
Pharmacology & Therapeutics (2016) Vol. 166, pp. 40-55
Closed Access | Times Cited: 139
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment
Marika Premoli, Francesca Aria, Sara Anna Bonini, et al.
Life Sciences (2019) Vol. 224, pp. 120-127
Closed Access | Times Cited: 114
Emerging drugs of abuse: current perspectives on synthetic cannabinoids
Danièle Debruyne, Reynald Le Boisselier
Substance Abuse and Rehabilitation (2015), pp. 113-113
Open Access | Times Cited: 106
Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
Larissa Staurengo‐Ferrari, Stephanie Badaro‐Garcia, M. Hohmann, et al.
Frontiers in Pharmacology (2019) Vol. 9
Open Access | Times Cited: 106
Polyunsaturated fatty acids and endocannabinoids in health and disease
Hércules Rezende Freitas, Alinny Rosendo Isaac, Renato Malcher‐Lopes, et al.
Nutritional Neuroscience (2017) Vol. 21, Iss. 10, pp. 695-714
Closed Access | Times Cited: 102
GPR55: A therapeutic target for Parkinson's disease?
Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez, et al.
Neuropharmacology (2017) Vol. 125, pp. 319-332
Closed Access | Times Cited: 91
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action
Maurício dos Santos Pereira, C.A. da-Silva, Francisco Silveira Guimarães, et al.
Neurobiology of Disease (2016) Vol. 94, pp. 179-195
Closed Access | Times Cited: 88
Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder
Asmat Ullah Khan, Muhammad Akram, Muhammad Daniyal, et al.
International Journal of Neuroscience (2018) Vol. 129, Iss. 1, pp. 55-93
Closed Access | Times Cited: 86
Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications
Zach J. Leinen, Rahul Mohan, Lakmini S. Premadasa, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2630-2630
Open Access | Times Cited: 33
Ferrosenescence: The iron age of neurodegeneration?
Adonis Sfera, Kelsey Bullock, Amy Price, et al.
Mechanisms of Ageing and Development (2017) Vol. 174, pp. 63-75
Closed Access | Times Cited: 78
Structural Insights into CB1 Receptor Biased Signaling
R.M. Al-Zoubi, Paula Morales, Patricia H. Reggio
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1837-1837
Open Access | Times Cited: 75
Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Iván Carrera, Ramón Cacabelos
Current Neuropharmacology (2018) Vol. 17, Iss. 3, pp. 295-306
Open Access | Times Cited: 67
Type-2 cannabinoid receptors in neurodegeneration
Tiziana Bisogno, Sergio Oddi, Alessandra Piccoli, et al.
Pharmacological Research (2016) Vol. 111, pp. 721-730
Closed Access | Times Cited: 66
Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs
Marianna Tosato, Valerio Di Marco
Biomolecules (2019) Vol. 9, Iss. 7, pp. 269-269
Open Access | Times Cited: 61
Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds
Elise Wouters, Jolien Walraed, Michael J. Robertson, et al.
ACS Pharmacology & Translational Science (2019) Vol. 3, Iss. 2, pp. 285-295
Open Access | Times Cited: 56
Apigenin Attenuates Functional and Structural Alterations via Targeting NF-kB/Nrf2 Signaling Pathway in LPS-Induced Parkinsonism in Experimental Rats
Mayank Patel, Shamsher Singh
Neurotoxicity Research (2022) Vol. 40, Iss. 4, pp. 941-960
Closed Access | Times Cited: 29
A recent update on drugs and alternative approaches for parkinsonism
Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty
Neuropeptides (2024) Vol. 104, pp. 102415-102415
Closed Access | Times Cited: 6
Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity
Adelina G. Meadows, J. H. Lee, Chia‐Shan Wu, et al.
International Journal of Obesity (2015) Vol. 40, Iss. 3, pp. 417-424
Closed Access | Times Cited: 60
Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures
Namyata Pathak- Gandhi, Ashok Vaidya
Journal of Ethnopharmacology (2016) Vol. 197, pp. 46-51
Closed Access | Times Cited: 55
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodríguez‐Cueto, Irene Santos‐García, Laura García‐Toscano, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 217-226
Closed Access | Times Cited: 52
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals
Yara Mouhamed, Andrey E. Vishnyakov, Bessi Qorri, et al.
Drug Healthcare and Patient Safety (2018) Vol. Volume 10, pp. 45-66
Open Access | Times Cited: 51
Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events
Colin Davidson, Jolanta Opacka‐Juffry, Ángel Arévalo‐Martín, et al.
Advances in pharmacology (2017), pp. 135-168
Closed Access | Times Cited: 49
Piperine in combination with quercetin halt 6-OHDA induced neurodegeneration in experimental rats: Biochemical and neurochemical evidences
Shamsher Singh, Puneet Kumar
Neuroscience Research (2017) Vol. 133, pp. 38-47
Closed Access | Times Cited: 49
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease
Marika Cordaro, Rosalba Siracusa, Rosalia Crupi, et al.
Molecular Neurobiology (2018) Vol. 55, Iss. 12, pp. 9251-9266
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top